Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma

Trial Profile

Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Polatuzumab vedotin (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 13 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 07 Jun 2016 Results comparing two phase I studies (JO29138 and DCS4968g ; n=7) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 11 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top